# A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

> **NCT07089706** · PHASE4 · RECRUITING · sponsor: **ModernaTX, Inc.** · enrollment: 832 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** mRNA-1283.251 Variant-containing Formulation

## Key facts

- **NCT ID:** NCT07089706
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-21
- **Primary completion:** 2026-05-11
- **Final completion:** 2026-05-11
- **Target enrollment:** 832 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07089706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07089706, "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07089706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*